

Number of Authorised Prescribers approved to prescribe Medicinal Cannabis  
Number of AP approvals (product)  
Total patients via AP pathway including indication and 6 monthly reporting numbers

From 1 August 2017 to 31 October 2019	From 1 July 2017 to 30 June 2019 For periods ending: 31 December 2017 30 June 2018 31 December 2018 30 June 2019
80	
204	
	555

**Total patients via AP pathway including indication and 6 monthly reporting numbers**

	New Patients initiated 01/07/17- 31/12/17	New Patients initiated 01/01/18- 30/06/18	New Patients initiated 01/07/18- 31/12/18	New Patients initiated 01/01/19- 30/06/19
anticonvulsant for children (<18 years) with severe refractory epilepsy	0	0	2	0
Cancer Pain	0	0	0	0
Cancer pain and or palliation, Chronic non-cancer pain (CNCP)	0	0	0	10
Cancer pain and symptom management	0	0	43	8
Cancer related pain +/- nausea and vomiting related to cancer treatment, Neuropathic pain, Insomnia, Anxiety, Restless Legs Syndrome, agitation and the behavioural and psychological symptoms of dementia	0	0	0	0
Cancer related pain +/- nausea and vomiting,	0	0	10	30
Chronic debilitating non-cancer pain	0	0	0	0
Cancer related pain and Chronic non-cancer pain	0	0	0	0
Cancer related pain, Cancer related nausea and vomiting, Neuropathic pain/fibromyalgia, Insomnia, Anxiety, Restless Legs Syndrome, Agitation and/or the behavioural and psychological symptoms of dementia	0	0	2	0
Cancer related pain, Chronic non cancer pain, Neuropathic pain associated with MS	0	0	5	7
Cancer related pain, Chronic non cancer pain, Neuropathic pain associated with MS	0	0	36	0
Chronic pain	0	0	1	4
Cancer related pain, Neuropathic pain, PTSD, insomnia	0	0	0	0
Chemotherapy induced nausea and vomiting	0	0	0	0
Chemotherapy induced nausea and vomiting	0	0	0	0
Pain, cachexia, and/or insomnia associate with cancer in palliative care	0	0	0	0
Chemotherapy induced vomiting	0	0	3	0
Chronic pain	1	23	10	0
Chronic pain, Cancer related pain +/- nausea and vomiting	0	1	26	0
Chronic pain, MS Spasticity, neuropathic pain, sleep disturbances, CINV, PTSD	0	0	13	0
Chronic persistent non-cancer related pain	0	0	0	0
chronic persistent non-cancer related pain, refractory to standard pain medications	0	0	0	0
Compassionate access to medicinal cannabis products, a small group of children with very severe intractable epilepsy.	0	0	0	0
Compassionate access to medicinal cannabis products, a small group of children with very severe intractable epilepsy. Patients must meet the inclusion criteria and are approved by an independent panel of the Office of Medicinal Cannabis, DHHS VIC.	0	0	0	0
Continuation of CAPS Pilot trial for young people with Refractory Anxiety disorders	0	0	0	0
Intractable Epilepsy	0	1	8	0
Neuropathic pain, PTSD, insomnia	0	0	0	0

Non-cancer pain (neuropathic pain)	0	0	0	1
Non-cancer pain (neuropathic pain)				
Cancer -related pain				
Chemotherapy-Induced Nausea & Vomiting (CINV)	0	0	0	0
Non-cancer pain (neuropathic pain), Cancer-related pain or Chemotherapy-Induced Nausea & Vomiting (CINV)	2	0	23	1
Non-cancer pain, cancer related pain and CINV	0	0	0	0
Palliative care patients with anorexia, weight loss, refractory chemotherapy induced nausea and vomiting	1	1	0	0
Patient meets the inclusion criteria and are approved by an independent panel of the Office of Medicinal Cannabis, DHHS VIC	0	1	1	0
Patients with advanced histologically proven cancer (metastatic or locally advanced)	0	0	0	0
Patients with chronic persistent non cancer related pain	0	21	10	20
patients with intractable cancer pain with or without chemotherapy-induced nausea and vomiting, when all other treatment and management strategies have not completely resolved symptoms, failed, contraindicated or have caused side effects	0	0	0	0
Refractory Epilepsy	0	0	1	0
Refractory Paediatric Epilepsy	89	105	2	0
Second line therapy for the management of intractable pain in advanced cancer patients, as an adjunct to opioid analgesia	0	9	15	0
Severe Refractory Epilepsy	0	0	8	0
Use as anticonvulsant for group of 40 eligible children (<18 years) with severe, refractory epilepsy.	0	0	0	0
<b>Total for each period</b>	<b>93</b>	<b>162</b>	<b>219</b>	<b>81</b>

## Total SAS B approvals by State and per Indication

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Achalasia			1							1
ADHD - Attention deficit disorder with hyperactivity			1		21					22
Aggressive behaviour					5	1		1		7
Agitation									1	1
Alzheimers dementia			1					7		8
Alzheimer's disease				6	4			10	6	26
Amyotrophic lateral sclerosis			3					1		4
Anaemia					1					1
Anorexia			181		42	6	1	7	7	244
Anxiety		3	336		533	11		286	18	1187
Appetite			2		7	1				10
Appetite control			2		1				2	5
Arthritis						2				2
Atopic dermatitis					2			2		4
Autism			13		26	2		5	1	47
Autism spectrum disorder		1	23		36	11		27	1	99
Behaviour management			2							2
Behavioural problem			2		2	3		3	1	11
Bipolar			1							1
Blood glucose management					1					1
Cachexia			2		3	1		2		8
Cancer pain and symptom management		41	543		607	41	1	386	89	1708
Chemotherapy induced vomiting			85		45	7		46	3	186
Chemotherapy-induced nausea and vomiting			3		12					15
Chronic pain	1	52	3262	4	5949	93		2537	707	12605
Complex regional pain syndrome (CRPS)				1				3		4
COPD				1		2				3
Crohn's disease				3		3		4		10
Dementia				4		6		9	2	21
Depression				7		3		3		13
Dermatitis						1				1

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Dyskinesia				1		1			1	3
Dyspnea						3				3
Dystonia				4		53			6	1
Epilepsy				33		12	7	10	46	39
Essential tremor									1	1
Fibromyalgia				15		8	3		78	6
Generalised anxiety disorder				5		2			2	9
Glioblastoma							4	2	6	12
Glioblastoma multiforme							1			1
Glioma							1		1	2
Grover's disease				1						1
Headache										1
Huntington chorea				1		2				10
Irritable bowel syndrome				3		1			3	7
Inflammatory bowel disease				5		7			20	32
Insomnia				50		132	1		45	10
Irritable bowel syndrome				2		2			6	10
Joint pain				1					1	2
Kearns-Sayre mitochondrial cytopathy				1						1
Memory loss										1
Meniere disease										1
Migraine				21		2			7	30
Migraine (disorder)				15		8			56	1
Mood disorder				6		8	2		10	26
Motor neurone disease				2		1			2	5
Movement disorder				17		8	1		6	1
Multiple sclerosis				29		22	2		21	17
Multiple sclerosis spasm and pain			1	13		21			8	43
Muscle rigidity					3					3
Muscle spasm				1		1	1			3
Muscle spasticity					1				2	3
Muscle wasting					1					1

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Muscular dystrophy								1		1
Myoclonic disorder				2		1		1		4
Nausea				26		7	17		13	2
Nausea and vomiting				5		9	7		2	23
Neuralgia								1		1
Neurological disorder				1						1
Neuropathic pain			7	913	1	286	35		187	294
Neuropathy					1				2	3
Oscillopsia								1		1
Osteoarthritis					1					1
Pain		1	57			7	8		28	12
Palliative							1		1	2
Palliative care				9		37	4		53	4
Panic disorder								2		2
Parkinson's disease		1	32		43				54	21
Peripheral neuropathy							1			1
Pityriasis rubra pilaris						1				1
Post-traumatic stress disorder				68		152	6		51	19
Psoriasis						1				1
Progressive supranuclear palsy								6		6
Psychogenic seizures					1					1
Refractory epilepsy		1	3		4	1			9	7
Refractory nausea and vomiting				2		1				3
Restless legs						2			2	4
Restless legs syndrome				7		2			5	14
Rheumatoid arthritis				3				3		6
Schizophrenia						4				4
Seizure				2		2	3		2	8
Seizure management		1	167		158	47	8	111	124	616
Sleep disorder				20		19			10	9
Sleep disturbance				4		1				5
Social anxiety disorder						1				1

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Spasticity			111		65	1		12	13	202
Tinnitus					2					2
Tourette's disorder			1							1
Tourette's syndrome			15		6			2		23
Tremor			8		15			9	7	39
Trigeminal neuralgia			1					5		6
Ulcerative colitis			3		2			12	1	18
Grand Total	1	109	6179	5	8434	333	22	4242	1457	20782